The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Escape from Flatland 2: complexity and promiscuity
Abstract
Toxicity plays a major role in attrition in the clinic and promiscuity has been linked to toxicity. A number of molecular descriptors have been identified that contribute to promiscuity including ionization and logP. In this study we report on the relationship between complexity, as measured by two descriptors [fraction sp3 (Fsp3) where Fsp3 = (number of sp3 hybridized carbons/total carbon count) and chiral carbon count], and promiscuity as well as Cyp450 inhibition. We find that increasing complexity reduces promiscuity and Cyp450 inhibition. As an understanding of key property descriptors has helped the pharmaceutical industry to address some of the deficiencies of compounds as pertains to bioavailability, awareness of the descriptors that impact promiscuity should allow us to better address toxicity in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
Self-citationCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
The Medicinal Chemist’s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates
Roughley, S. D., & Jordan, A. M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200187y · Cited by 2,725
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Martin, Y. C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0492002 · Cited by 1,020
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Predicting in vivo drug interactions from in vitro drug discovery data
Wienkers, L. C., & Heath, T. G. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1851 · Cited by 904
Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877
What Do Medicinal Chemists Actually Make? A 50-Year Retrospective
Walters, W. P., Green, J., Weiss, J. R., & Murcko, M. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200504p · Cited by 387
Kramer, J. A., Sagartz, J. E., & Morris, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2378 · Cited by 372
Cooper, T. W. J., Campbell, I. B., & Macdonald, S. J. F. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201002238 · Cited by 299
Booth, B., & Zemmel, R. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1384 · Cited by 278
Getting pharmaceutical R&D back on target
Bunnage, M. E. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.581 · Cited by 258
Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data
Azzaoui, K., Hamon, J., Faller, B., Whitebread, S., Jacoby, E., Bender, A., Jenkins, J. L., & Urban, L. (2007) · ChemMedChem · doi:10.1002/cmdc.200700036 · Cited by 176
Molecular complexity and fragment-based drug discovery: ten years on
Leach, A. R., & Hann, M. M. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.05.008 · Cited by 169
Peters, J., Schnider, P., Mattei, P., & Kansy, M. (2009) · ChemMedChem · doi:10.1002/cmdc.200800411 · Cited by 156
On the origins of drug polypharmacology
Jalencas, X., & Mestres, J. (2012) · MedChemComm · doi:10.1039/c2md20242e · Cited by 143
Can we discover pharmacological promiscuity early in the drug discovery process?
Peters, J., Hert, J., Bissantz, C., Hillebrecht, A., Gerebtzoff, G., Bendels, S., Tillier, F., Migeon, J., Fischer, H., Guba, W., et al. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.001 · Cited by 87
Enthalpic Efficiency of Ligand Binding
Ferenczy, G. G., & Keserű, G. M. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100125a · Cited by 64
Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models
Gleeson, M. P., Davis, A. M., Chohan, K. K., Paine, S. W., Boyer, S. K., Gavaghan, C. L., Arnby, C. H., Kankkonen, C., & Albertson, N. H. (2007) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-007-9139-6 · Cited by 64
Comparing Measures of Promiscuity and Exploring Their Relationship to Toxicity
Wang, X., & Greene, N. (2012) · Molecular Informatics · doi:10.1002/minf.201100148 · Cited by 27
PredictingIn VivoSafety Characteristics Using Physiochemical Properties andIn VitroAssays
Greene, N., & Song, M. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.89 · Cited by 11
Cited by
The use of spirocyclic scaffolds in drug discovery
Zheng, Y., Tice, C. M., & Singh, S. B. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.06.081 · Cited by 1,036
Transition metal–catalyzed alkyl-alkyl bond formation: Another dimension in cross-coupling chemistry
Choi, J., & Fu, G. C. (2017) · Science · doi:10.1126/science.aaf7230 · Cited by 1,007
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design
Subbaiah, M. A. M., & Meanwell, N. A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01215 · Cited by 710
Metals to combat antimicrobial resistance
Frei, A., Verderosa, A. D., Elliott, A. G., Zuegg, J., & Blaskovich, M. A. T. (2023) · Nature Reviews Chemistry · doi:10.1038/s41570-023-00463-4 · Cited by 638
Metadata
- Authors
- Lovering, F.
- Venue
- MedChemComm
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2013
- Volume
- 4
- Issue
- 3
- Pages
- 515
- ISSN
- 2040-2503 (ISSN-L)
- 2040-2511
- OpenAlex
- W2096095251
- Cited by
- 1,444
- References
- 25
- FWCI
- 22.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.